Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4369 The predictive value of 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG PET/CT in patients with paragangliomas

Introduction: Paragangliomas (PGLs) are rare neuroendocrine tumours with variable clinical outcomes. Early identification of prognostic markers is essential for effective disease management. PET/CT imaging with 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG offers unique insights into tumour biology, respectively.

Conference:

Presenting Author: Xu J

Authors: Gao J, Xu J, Liang Y, Chen J, Song S,

Keywords: PET/CT, paraganglioma, prognosis,

#4339 Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN)

Introduction: Accurate contouring for [68Ga]DOTATATE PET in NEN is challenging due to differing physiological uptake for the liver, spleen and other organs. This poses a significant problem for absolute thresholding algorithms using a single threshold, even if the threshold is based on liver uptake (as suggested for FDG PET by PERCIST). Improved contouring of PET to measure [68Ga]DOTATATE-avid tumour volume could help clinical translation of this potential biomarker.

Conference:

Presenting Author: Chan D

Authors: Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z,

Keywords: prognostic biomarker, PET imaging, [68Ga]DOTATATE, Total Lesion Volume,

#4327 Metastatic non-functional pancreatic neuroendocrine tumour with transformation to insulinoma shown on 68Ga-Exendin-4 PET/CT

Introduction: 68Ga-exendin-4 PET/CT imaging has been utilised for benign insulinomas. However, some reports demonstrated the absence of GLP-1R expression of malignant insulinomas.

Conference:

Presenting Author:

Authors: Gao J, Xu J, Liang Y, Chen J, Song S,

Keywords: pancreatic neuroendocrine tumour, PET/CT, insulinoma, 68Ga-exendin-4,

#4310 [18F]AlF-NOTA-octreotide as tracer for somatostatin receptor PET/CT: Retrospective analysis of the clinical use in 288 neuroendocrine tumour patients

Introduction: [18F]AlF-NOTA-octreotide has emerged as a reliable tracer for somatostatin receptor (SSTR) PET/CT in patients with neuroendocrine neoplasms (NENs). Although effective and logistically advantageous, there remains limited data on its routine clinical application, particularly for specific NEN subtypes (e.g. NET G3).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Dekervel J, Cleeren F, Goffin K, Dooms C,

Keywords: [18F]AlF-NOTA-octreotide, routine clinical use, neuroendocrine tumour, somatostatin receptor, PET/CT imaging,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,